达罗他胺联合亮丙瑞林与依西美坦治疗复发性成人型卵巢颗粒细胞瘤的II期研究
这项单臂II期研究评估达罗他胺、依西美坦和亮丙瑞林治疗既往芳香化酶抑制剂进展的复发性成人型卵巢颗粒细胞瘤的疗效与安全性;
要点
- 该联合方案在复发性成人型卵巢颗粒细胞瘤中客观缓解率低(6.25%),未达主要终点。
- 中位无进展生存期8.5个月,提示具有一定临床意义的疾病控制。
- 未观察到归因于治疗方案的4级或5级不良事件。
核心结论
- 尽管试验未达到主要终点,该联合方案仍观察到1例部分缓解,并显示出具有临床意义的无进展生存期。
研究设计与样本
- 单臂II期协作组研究,纳入既往芳香化酶抑制剂治疗后进展的复发性成人型卵巢颗粒细胞瘤患者,采用Simon最优两阶段设计,目标样本量基于该设计确定。
- 治疗方案为达罗他胺600 mg口服每日两次、依西美坦25 mg口服每日一次、亮丙瑞林7.5 mg肌内注射每四周一次。
- 主要疗效指标为按RECIST 1.1评估的客观缓解率,次要指标包括缓解持续时间、无进展生存期、总生存期和安全性。
主要发现
- 16例可评估患者中,1例部分缓解,客观缓解率为6.25%。
- 中位无进展生存期为8.5个月(95% CI:3.1个月至12.0个月),中位总生存期未达到。
- 未出现归因于治疗方案的4级或5级不良事件。
- 因未达到预设终点,试验未继续进入第二阶段。
关键数值与推荐
- 客观缓解率(ORR)为6.25%(1/16例可评估患者)。
- 中位无进展生存期为8.5个月(95% CI:3.1个月至12.0个月)。
- 试验注册号为NCT06169124。
临床怎么用
- 该联合方案在既往芳香化酶抑制剂进展的复发性成人型卵巢颗粒细胞瘤中客观缓解率有限,不支持作为该人群的优先选择。
- 观察到的中位无进展生存期8.5个月及可控的安全性,可为后续研究设计或个体化治疗讨论提供参考。
局限性
- 因未达到预设终点而未进入第二阶段,疗效评估受限。
- 中位总生存期未达到,长期生存获益尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the efficacy and safety of darolutamide, exemestane, and leuprolide acetate in recurrent adult-type ovarian granulosa cell tumor (AGCT). METHODS: This single-arm Phase II cooperative group study included patients with recurrent AGCT who had progressed on a prior aromatase inhibitor. The treatment regimen consisted of darolutamide 600 mg by mouth twice daily, exemestane 25 mg by mouth once daily, and leuprolide acetate 7.5 mg by intramuscular injection every four weeks. Patient accrual occurred from January 2024 to April 2024 with sample size determined using Simon's Optimal two-stage design. The primary measure of efficacy was objective response rate (ORR) measured by Response Evaluation Criteria in Solid Tumors 1.1. Secondary objectives included duration of response, progression-free survival (PFS), overall survival (OS), and safety of the treatment regimen. RESULTS: Seventeen patients were enrolled to complete target accrual of the first stage. Of the 16 evaluable patients, there was one partial response (ORR = 6.25%). The trial did not continue to the second stage as it did not meet its prespecified endpoint. Ten patients (62.5%) were confirmed to have stable disease and five patients (31.25%) were confirmed to have progressive disease. Median PFS was 8.5 months (95% CI: 3.1 months - 12.0 months). Median OS was not reached. There were no grade 4 or grade 5 adverse events attributable to the treatment regimen. CONCLUSIONS: Though the trial did not meet its primary endpoint, there was one partial response to the treatment regimen. Clinically meaningful PFS was demonstrated. Clinical Trial Registration Number NCT06169124.
引用
- Hopp EE, Enserro D, Campos S, et al. A phase II study of androgen receptor inhibition by darolutamide in combination with leuprolide acetate and exemestane in recurrent adult-type ovarian granulosa cell tumor. Gynecol Oncol. 2026. PMID: 42574969. doi:10.1016/j.ygyno.2026.07.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。